Merit Medical Systems, Inc. (NASDAQ:MMSI) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analyst consensus: MarketBeat reports an average rating of "Moderate Buy" from 11 analysts (8 buy, 3 hold) with a 12‑month target of $103.33, versus a recent share price near $69.7.
• Quarterly beat and guidance: Merit reported $1.04 EPS vs. $0.96 expected and $393.94M revenue (up 10.9% YoY), and issued FY2026 EPS guidance of $4.010–$4.150.
• Institutional interest: Hedge funds and institutions own 99.66% of the stock, with notable increases such as Goldman Sachs raising its stake to 719,313 shares; the company has a market cap of ~$4.14B and a P/E of 32.88.

Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) has received an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $103.3333.

Several analysts have issued reports on MMSI shares. Canaccord Genuity Group increased their target price on shares of Merit Medical Systems from $93.00 to $99.00 and gave the stock a "buy" rating in a research note on Wednesday, December 17th. Weiss Ratings reiterated a "hold (c)" rating on shares of Merit Medical Systems in a research report on Monday, December 29th. BTIG Research initiated coverage on Merit Medical Systems in a report on Friday, February 6th. They set a "buy" rating and a $107.00 price objective for the company. Wells Fargo & Company cut shares of Merit Medical Systems from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $95.00 to $78.00 in a research report on Thursday, February 26th. Finally, Zacks Research downgraded shares of Merit Medical Systems from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, November 18th.

Merit Medical Systems Price Performance

Merit Medical Systems stock opened at $69.71 on Wednesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 4.34 and a quick ratio of 2.95. Merit Medical Systems has a one year low of $69.56 and a one year high of $107.27. The firm has a market capitalization of $4.14 billion, a P/E ratio of 32.88, a PEG ratio of 2.08 and a beta of 0.62. The business has a fifty day moving average price of $81.50 and a 200-day moving average price of $84.17.

Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last issued its earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 EPS for the quarter, topping the consensus estimate of $0.96 by $0.08. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The business had revenue of $393.94 million during the quarter, compared to the consensus estimate of $390.77 million. During the same quarter last year, the company earned $0.93 EPS. The firm's revenue was up 10.9% compared to the same quarter last year. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, equities research analysts forecast that Merit Medical Systems will post 3.37 EPS for the current year.

Institutional Trading of Merit Medical Systems

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC grew its position in Merit Medical Systems by 7.3% in the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier's stock worth $1,730,000 after acquiring an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Merit Medical Systems by 16.9% during the first quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier's stock valued at $76,039,000 after purchasing an additional 103,878 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Merit Medical Systems by 0.5% during the second quarter. Bank of New York Mellon Corp now owns 428,084 shares of the medical instruments supplier's stock worth $40,017,000 after purchasing an additional 2,261 shares during the last quarter. Wedbush Securities Inc. lifted its stake in Merit Medical Systems by 26.3% during the second quarter. Wedbush Securities Inc. now owns 2,653 shares of the medical instruments supplier's stock worth $248,000 after purchasing an additional 553 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Merit Medical Systems in the 2nd quarter worth about $1,147,000. Hedge funds and other institutional investors own 99.66% of the company's stock.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company's product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.